Ridaforolimus pharmacokinetics in fed or fasting subjects

Trial Profile

Ridaforolimus pharmacokinetics in fed or fasting subjects

Phase of Trial: Phase I

Latest Information Update: 22 Aug 2012

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Breast cancer; Cancer; Endometrial cancer; Neurodegenerative disorders; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Merck & Co
  • Most Recent Events

    • 12 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top